表紙:嚢胞性線維症(CF)-2030年までの疫学予測
市場調査レポート
商品コード
1026631

嚢胞性線維症(CF)-2030年までの疫学予測

Cystic Fibrosis (CF) - Epidemiology Forecast to 2030

出版日: | 発行: GlobalData | ページ情報: 英文 41 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
嚢胞性線維症(CF)-2030年までの疫学予測
出版日: 2021年08月31日
発行: GlobalData
ページ情報: 英文 41 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7ヶ国市場(米国、フランス、ドイツ、イタリア、スペイン、英国、カナダ)における嚢胞性線維症(CF)の有病率の診断数は、今後10年間で0.51%のAGRで増加し、2020年の6万9,134例から、2030年には7万2,659例になると予測されています。2020年のCFの変異タイプは、F508delが最も多く、主要7ヶ国市場におけるCFの診断された有病者数の80.51%を占めています。

新生児スクリーニングプログラムの普及に伴い、CFはこれまでよりも早い時期に発見され、治療を開始することができるようになりました。CF患者の治療とケアの継続的な改善により、CF患者の寿命が延びることにより、診断された有病者数も増加すると予測されています。

当レポートは、嚢胞性線維症(CF)について調査しています。主要7ヶ国市場(米国、フランス、ドイツ、イタリア、スペイン、英国、カナダ)に焦点を当て、リスク要因、併存疾患、動向、年齢・性別の診断された有病者の10年間の疫学予測および洞察、COVID-19の影響などの情報を提供しています。

目次

第1章 嚢胞性線維症:エグゼクティブサマリー

  • 触媒
  • 関連レポート
  • 今後のレポート

第2章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界および過去の動向
  • 予測調査手法
  • CFの疫学予測(2020-2030)
    • 登録ベースの診断されたCF有病者数
    • 年齢別:登録ベースの診断されたCF有病者数
    • 性別:登録ベースの診断されたCF有病者数
    • 特定の変異を伴う登録ベースの診断されたCF有病者数
    • 慢性MRSA感染を伴う登録ベースの診断されたCF有病者数
    • 過小評価のために調整された登録ベースの診断されたCF有病者数
    • 年齢別:過小評価のために調整された登録ベースの診断されたCF有病者数
    • 性別:過小評価のために調整された登録ベースの診断されたCF有病者数
    • 過小評価のために調整された特定の突然変異を伴う登録ベースの診断されたCF有病者数
    • 過小評価のために調整された慢性MRSA感染を伴う登録ベースの診断されたCF有病者数
  • 議論
    • 疫学的予測の洞察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第3章 付録

  • 参考文献
  • 著者について
  • お問い合わせ
図表

List of Tables

List of Tables

  • Table 1: Summary of Updated Data Types, Registry-Based Forecast
  • Table 2: Summary of Updated Data Types, Registry-Based Forecast Adjusted for Underestimation
  • Table 3: Risk Factors and Comorbidities for CF

List of Figures

List of Figures

  • Figure 1: 7MM, Registry-Based Diagnosed Prevalent Cases of CF, Both Sexes, All Ages, 2020 and 2030
  • Figure 2: 7MM, Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, Both Sexes, All Ages, 2020 and 2030
  • Figure 3: 7MM, Registry-Based Diagnosed Prevalence of CF, Men and Women, All Ages, 2010-2030 (%)
  • Figure 4: 7MM, Registry-Based Diagnosed Prevalence of CF Adjusted for Underestimation, Men and Women, All Ages, 2010-2030 (%)
  • Figure 5: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF
  • Figure 6: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF by Specific Mutation
  • Figure 7: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection
  • Figure 8: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation
  • Figure 9: Registry-Based Diagnosed Prevalent Cases of CF, 7MM, Men and Women, All Ages, 2020
  • Figure 10: 7MM, Age-Specific Registry-Based Diagnosed Prevalent Cases of CF, Men and Women, 2020 (N)
  • Figure 11: 7MM, Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF, All Ages, 2020 (N)
  • Figure 12: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations, Men and Women, All Ages, 2020 (N)
  • Figure 13: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Men and Women, All Ages, 2020 (N)
  • Figure 14: Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, 7MM, Men and Women, All Ages, 2020
  • Figure 15: 7MM, Age-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, Men and Women, 2020 (N)
  • Figure 16: 7MM, Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, All Ages, 2020 (N)
  • Figure 17: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Mutations Adjusted for Underestimation, Men and Women, All Ages, 2020 (N)
  • Figure 18: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection Adjusted for Underestimation, Men and Women, All Ages, 2020 (N)
目次
Product Code: GDHCER278-21

Cystic fibrosis (CF) is a progressive, inherited disorder that primarily affects the respiratory and digestive systems. In people with CF, mucus, sweat, and other fluids produced in these systems are sticky and thick, and may obstruct the passageways in the lungs and pancreas (Mayo Clinic, 2021). Mucus build-up and airway blockages in the lungs cause symptoms such as persistent cough, wheezing, inflamed nasal passages, and recurrent lung infections. Impacts on the digestive system can lead to chronic constipation, intestinal blockages, and weight loss (Mayo Clinic, 2021).

GlobalData epidemiologists utilized comprehensive, country-specific data from national CF registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of CF. For all the 7MM, CF cases were segmented by age, sex, mutation type, and MRSA infection. Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes in prevalence throughout the forecast period.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of CF in the 7MM will grow by an annual growth rate (AGR) of 0.51% over the next 10 years, from 69,134 cases in 2020 to 72,659 cases in 2030. For CF mutation type in 2020, the F508del was the most prevalent gene mutation, representing 80.51% of diagnosed prevalent cases of CF in the 7MM. With the more widespread implementation of newborn screening programs, CF is now detected, and thus intervention can begin, earlier than ever. GlobalData epidemiologists expect that continued improvements in the treatment and care of CF patients may drive the number of diagnosed prevalent cases higher as people with CF live longer.

Scope

  • The Cystic Fibrosis Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Cystic Fibrosis (CF) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CF segmented by age (0-1, 2-5, 6-11, 12-17, 18-29 years, and by 10-year age groups up to 80 years and older) and sex. Diagnosed prevalent cases of CF are further segmented by specific mutation type and chronic methicillin-resistant Staphylococcus aureus (MRSA) infection.
  • The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The CF Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CF markets.
  • Quantify patient populations in the global CF markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.
  • Understand magnitude of the CF population by age, sex, mutation type, and MRSA infection.

Table of Contents

Table of Contents

1 Cystic Fibrosis: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
    • 2.3.1 Registry-Based Diagnosed Prevalence of CF
    • 2.3.2 Registry-Based Diagnosed Prevalent Cases Adjusted for Underestimation
  • 2.4 Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Sources Not Used
    • 2.4.3 Forecast Assumptions and Methods
    • 2.4.4 Registry-Based Diagnosed Prevalent Cases of CF
    • 2.4.5 Registry-Based Diagnosed Prevalent Cases of CF by Specific Mutation
    • 2.4.6 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection
    • 2.4.7 Registry-Based Diagnosed Prevalent Cases Adjusted for Underestimation
  • 2.5 Epidemiological Forecast for CF (2020-2030)
    • 2.5.1 Registry-Based Diagnosed Prevalent Cases of CF
    • 2.5.2 Age-Specific Registry-Based Diagnosed Prevalent Cases of CF
    • 2.5.3 Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF
    • 2.5.4 Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations
    • 2.5.5 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection
    • 2.5.6 Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation
    • 2.5.7 Age-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation
    • 2.5.8 Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation
    • 2.5.9 Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations Adjusted for Underestimation
    • 2.5.10 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection Adjusted for Underestimation
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of Analysis
    • 2.6.4 Strengths of Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us